{"commentary":{"count":31,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":13,"podcast":11,"youtube":7},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03755791\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"COSMIC-312","nct_id":"NCT03755791","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cosmic-312-nct03755791. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"COSMIC-312","arms":[{"description":"Participants with advanced HCC will receive cabozantinib 40 milligrams (mg) oral, once daily (qd) + atezolizumab 1200 mg infusion, once every 3 weeks (q3w)","label":"Experimental arm","type":"EXPERIMENTAL"},{"description":"Participants with advanced HCC will receive sorafenib 400 mg twice a day (bid)","label":"Control arm","type":"ACTIVE_COMPARATOR"},{"description":"Participants with advanced HCC will receive cabozantinib 60 mg qd","label":"Single-Agent Cabozantinib arm","type":"OTHER"}],"collaborators":[],"completion_date":{"date":"2026-07-31","type":"ESTIMATED"},"conditions":["Hepatocellular Carcinoma"],"enrollment":{"count":837,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Cabozantinib","type":"DRUG"},{"name":"Cabozantinib","type":"DRUG"},{"name":"Sorafenib","type":"DRUG"},{"name":"Atezolizumab","type":"DRUG"}],"last_update":"2025-12-11","lead_sponsor":"Exelixis","official_title":"A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2021-11-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population","timeFrame":"From the date of first participant randomization up to 28 months"},{"measure":"Overall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population","timeFrame":"From the date of first participant randomization up to 36 months"}],"references":[{"citation":"Yau T, Kaseb A, Cheng AL, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Milwee S, Wang Z, Curran D, Kelley RK, Rimassa L. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):310-322. doi: 10.1016/S2468-1253(23)00454-5. Epub 2024 Feb 13.","pmid":"38364832","type":"DERIVED"},{"citation":"Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4.","pmid":"35798016","type":"DERIVED"},{"citation":"Kelley RK, W Oliver J, Hazra S, Benzaghou F, Yau T, Cheng AL, Rimassa L. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. Future Oncol. 2020 Jul;16(21):1525-1536. doi: 10.2217/fon-2020-0283. Epub 2020 Jun 3.","pmid":"32491932","type":"DERIVED"}],"start_date":{"date":"2018-06-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy","url":"https://clinicaltrials.gov/study/NCT03755791"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cosmic-312-nct03755791"}